TNF and rheumatoid arthritis: bDMARDs successfully delay RA progression, alleviate symptoms, and improve the overall quality of life by targeting specific proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), IL-1, and IL-6 (1).